In agreement with this activated ERα genetic signature, STAT1-/- mammary tumor is also a unique preclinical model because of its sensitivity to standard endocrine therapy, including estrogen deprivation therapy (this study) and treatment targeting ERα (AM Fowler and MJ Welch, manuscript in preparation). This evidence concerns the gene STAT1 and breast cancer.